Cargando…
Efficacy of HE4, CA125, Risk of Malignancy Index and Risk of Ovarian Malignancy Index to Detect Ovarian Cancer in Women with Presumed Benign Ovarian Tumours: A Prospective, Multicentre Trial
Background: Presumed benign ovarian tumours (PBOT) are defined by the International Ovarian Tumour Analysis (IOTA) group, without suspected sonographic criteria of cancer, without ascites or metastasis. The aim is to evaluate the efficacy of human epididymis protein 4 (HE4), cancer antigen 125 (CA12...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912210/ https://www.ncbi.nlm.nih.gov/pubmed/31699959 http://dx.doi.org/10.3390/jcm8111784 |
_version_ | 1783479402028335104 |
---|---|
author | Dochez, Vincent Randet, Mélanie Renaudeau, Céline Dimet, Jérôme Le Thuaut, Aurélie Winer, Norbert Thubert, Thibault Vaucel, Edouard Caillon, Hélène Ducarme, Guillaume |
author_facet | Dochez, Vincent Randet, Mélanie Renaudeau, Céline Dimet, Jérôme Le Thuaut, Aurélie Winer, Norbert Thubert, Thibault Vaucel, Edouard Caillon, Hélène Ducarme, Guillaume |
author_sort | Dochez, Vincent |
collection | PubMed |
description | Background: Presumed benign ovarian tumours (PBOT) are defined by the International Ovarian Tumour Analysis (IOTA) group, without suspected sonographic criteria of cancer, without ascites or metastasis. The aim is to evaluate the efficacy of human epididymis protein 4 (HE4), cancer antigen 125 (CA125), the risk of malignancy index (RMI) and the risk of ovarian malignancy index (ROMA) to predict ovarian cancer in women with PBOT. Methods: It is a prospective, observational, multicentre, laboratory-based study including women with PBOT in four hospitals from 11 May 2015 through 12 May 2016. Preoperative CA125 and HE4 plasma levels were measured for all women. The primary endpoint was the specificity of CA125 and HE4 for diagnosing ovarian cancer. The main secondary endpoints were specificity and likelihood ratio of RMI, ROMA and tumours markers. Results: Two hundred and fifty patients were initially enrolled and 221 patients were finally analysed, including 209 benign ovarian tumours (94.6%) and 12 malignant ovarian tumours (5.4%). The malignant group had significantly higher mean values of HE4, CA125, RMI and ROMA compared to the benign group (p < 0.001). Specificity was significantly higher using a combination of HE4 and CA125 (99.5%) compared to either HE4 or CA125 alone (90.4% and 91.4%, respectively, p < 0.001). Moreover, the positive likelihood ratio for combination HE4 and CA125 was significantly higher (104.5; 95% CI 13.6–800.0) compared to HE4 alone (5.81; 95% CI 2.83–11.90) or CA125 alone (6.97; 95% CI 3.91–12.41). Conclusions: The combination of HE4 and CA125 represents the best tool to predict the risk of ovarian cancer in patients with a PBOT. |
format | Online Article Text |
id | pubmed-6912210 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-69122102020-01-02 Efficacy of HE4, CA125, Risk of Malignancy Index and Risk of Ovarian Malignancy Index to Detect Ovarian Cancer in Women with Presumed Benign Ovarian Tumours: A Prospective, Multicentre Trial Dochez, Vincent Randet, Mélanie Renaudeau, Céline Dimet, Jérôme Le Thuaut, Aurélie Winer, Norbert Thubert, Thibault Vaucel, Edouard Caillon, Hélène Ducarme, Guillaume J Clin Med Article Background: Presumed benign ovarian tumours (PBOT) are defined by the International Ovarian Tumour Analysis (IOTA) group, without suspected sonographic criteria of cancer, without ascites or metastasis. The aim is to evaluate the efficacy of human epididymis protein 4 (HE4), cancer antigen 125 (CA125), the risk of malignancy index (RMI) and the risk of ovarian malignancy index (ROMA) to predict ovarian cancer in women with PBOT. Methods: It is a prospective, observational, multicentre, laboratory-based study including women with PBOT in four hospitals from 11 May 2015 through 12 May 2016. Preoperative CA125 and HE4 plasma levels were measured for all women. The primary endpoint was the specificity of CA125 and HE4 for diagnosing ovarian cancer. The main secondary endpoints were specificity and likelihood ratio of RMI, ROMA and tumours markers. Results: Two hundred and fifty patients were initially enrolled and 221 patients were finally analysed, including 209 benign ovarian tumours (94.6%) and 12 malignant ovarian tumours (5.4%). The malignant group had significantly higher mean values of HE4, CA125, RMI and ROMA compared to the benign group (p < 0.001). Specificity was significantly higher using a combination of HE4 and CA125 (99.5%) compared to either HE4 or CA125 alone (90.4% and 91.4%, respectively, p < 0.001). Moreover, the positive likelihood ratio for combination HE4 and CA125 was significantly higher (104.5; 95% CI 13.6–800.0) compared to HE4 alone (5.81; 95% CI 2.83–11.90) or CA125 alone (6.97; 95% CI 3.91–12.41). Conclusions: The combination of HE4 and CA125 represents the best tool to predict the risk of ovarian cancer in patients with a PBOT. MDPI 2019-10-25 /pmc/articles/PMC6912210/ /pubmed/31699959 http://dx.doi.org/10.3390/jcm8111784 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Dochez, Vincent Randet, Mélanie Renaudeau, Céline Dimet, Jérôme Le Thuaut, Aurélie Winer, Norbert Thubert, Thibault Vaucel, Edouard Caillon, Hélène Ducarme, Guillaume Efficacy of HE4, CA125, Risk of Malignancy Index and Risk of Ovarian Malignancy Index to Detect Ovarian Cancer in Women with Presumed Benign Ovarian Tumours: A Prospective, Multicentre Trial |
title | Efficacy of HE4, CA125, Risk of Malignancy Index and Risk of Ovarian Malignancy Index to Detect Ovarian Cancer in Women with Presumed Benign Ovarian Tumours: A Prospective, Multicentre Trial |
title_full | Efficacy of HE4, CA125, Risk of Malignancy Index and Risk of Ovarian Malignancy Index to Detect Ovarian Cancer in Women with Presumed Benign Ovarian Tumours: A Prospective, Multicentre Trial |
title_fullStr | Efficacy of HE4, CA125, Risk of Malignancy Index and Risk of Ovarian Malignancy Index to Detect Ovarian Cancer in Women with Presumed Benign Ovarian Tumours: A Prospective, Multicentre Trial |
title_full_unstemmed | Efficacy of HE4, CA125, Risk of Malignancy Index and Risk of Ovarian Malignancy Index to Detect Ovarian Cancer in Women with Presumed Benign Ovarian Tumours: A Prospective, Multicentre Trial |
title_short | Efficacy of HE4, CA125, Risk of Malignancy Index and Risk of Ovarian Malignancy Index to Detect Ovarian Cancer in Women with Presumed Benign Ovarian Tumours: A Prospective, Multicentre Trial |
title_sort | efficacy of he4, ca125, risk of malignancy index and risk of ovarian malignancy index to detect ovarian cancer in women with presumed benign ovarian tumours: a prospective, multicentre trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912210/ https://www.ncbi.nlm.nih.gov/pubmed/31699959 http://dx.doi.org/10.3390/jcm8111784 |
work_keys_str_mv | AT dochezvincent efficacyofhe4ca125riskofmalignancyindexandriskofovarianmalignancyindextodetectovariancancerinwomenwithpresumedbenignovariantumoursaprospectivemulticentretrial AT randetmelanie efficacyofhe4ca125riskofmalignancyindexandriskofovarianmalignancyindextodetectovariancancerinwomenwithpresumedbenignovariantumoursaprospectivemulticentretrial AT renaudeauceline efficacyofhe4ca125riskofmalignancyindexandriskofovarianmalignancyindextodetectovariancancerinwomenwithpresumedbenignovariantumoursaprospectivemulticentretrial AT dimetjerome efficacyofhe4ca125riskofmalignancyindexandriskofovarianmalignancyindextodetectovariancancerinwomenwithpresumedbenignovariantumoursaprospectivemulticentretrial AT lethuautaurelie efficacyofhe4ca125riskofmalignancyindexandriskofovarianmalignancyindextodetectovariancancerinwomenwithpresumedbenignovariantumoursaprospectivemulticentretrial AT winernorbert efficacyofhe4ca125riskofmalignancyindexandriskofovarianmalignancyindextodetectovariancancerinwomenwithpresumedbenignovariantumoursaprospectivemulticentretrial AT thubertthibault efficacyofhe4ca125riskofmalignancyindexandriskofovarianmalignancyindextodetectovariancancerinwomenwithpresumedbenignovariantumoursaprospectivemulticentretrial AT vauceledouard efficacyofhe4ca125riskofmalignancyindexandriskofovarianmalignancyindextodetectovariancancerinwomenwithpresumedbenignovariantumoursaprospectivemulticentretrial AT caillonhelene efficacyofhe4ca125riskofmalignancyindexandriskofovarianmalignancyindextodetectovariancancerinwomenwithpresumedbenignovariantumoursaprospectivemulticentretrial AT ducarmeguillaume efficacyofhe4ca125riskofmalignancyindexandriskofovarianmalignancyindextodetectovariancancerinwomenwithpresumedbenignovariantumoursaprospectivemulticentretrial |